Treatment-Resistant Depression Global Market Report 2025
상품코드:1751144
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 175 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
치료 저항성 우울증 시장 규모는 향후 몇 년 동안 강력한 성장세를 보일 것으로 예상되며, 2029년에는 연평균 6.9%의 CAGR로 24억 6,000만 달러에 달할 것으로 예상됩니다. 예측 기간 동안의 성장은 만성질환의 증가, 불안 장애의 유병률 증가, 정신건강 문제에 대한 인식 증가, 정부의 노력 강화, 의료 지출 증가 등의 요인에 기인할 것으로 보입니다. 예측 기간 동안 예상되는 주요 동향으로는 원격의료 및 디지털 헬스 확대, 진단 및 치료 기술의 발전, 정신건강에 대한 편견 감소 및 인식 개선 노력, 맞춤형 의료의 도입, 정신건강 치료에 인공지능의 통합 등이 있습니다.
정신장애의 유병률 증가는 치료 저항성 우울증(TRD) 시장의 성장을 촉진할 것으로 예상됩니다. 정신장애는 개인의 인지, 정서, 행동 기능에 영향을 미치는 다양한 상태를 포함하며, 많은 경우 일상 생활에 심각한 고통과 장애를 초래합니다. 이러한 질환의 높은 유병률은 유전적 소인과 같은 요인에 영향을 받습니다. 유전적 돌연변이는 뇌 화학을 변화시켜 우울증, 불안증, 정신분열증과 같은 질병에 대한 감수성을 증가시키기 때문에 TRD는 표준 치료가 효과가 없을 때 보다 개인화된 고급 치료 옵션을 제공함으로써 환자를 지원하고 회복 가능성과 전반적인 삶의 질을 향상시킬 수 있습니다. 예를 들어, 2023년 11월 미국심리학회(APA)는 18-34세 성인의 50%가 정신질환을 경험했으며, 이는 연령대 중 가장 높은 비율로 나타났다고 보고했습니다. 이러한 정신질환의 증가가 치료 저항성 우울증 시장의 성장에 기여하고 있습니다.
치료 저항성 우울증 시장의 주요 기업들은 환자의 미충족 수요를 충족시키고, 효능을 개선하며, 부작용을 최소화하기 위해 단제 요법과 같은 혁신적인 치료법 개발에 주력하고 있습니다. 단일요법은 여러 가지 치료법을 병용하는 것이 아니라 단일 치료법이나 약물을 사용하는 것으로, 치료 저항성 우울증 치료에 보다 집중적인 접근법을 제공합니다. 이 전략은 여러 약물에 반응하지 않는 환자에게 특히 유용합니다. 예를 들어, 2025년 1월 미국 제약 및 의료 기술 기업 존슨앤드존슨 서비스(Johnson & Johnson Services)는 SPRAVATO(에스케타민) 비강 스프레이가 미국 식품의약국(FDA)의 승인을 받아 성인의 치료 저항성 우울증에 대한 즉각적인 치료제로 승인되었다고 발표했습니다. SPRAVATO는 환자가 적어도 두 가지 이상의 다른 항우울제로 충분한 효과를 얻지 못한 경우 경구용 항우울제와 병용하여 사용됩니다. 이 약물의 빠른 효과는 효과가 나타나기까지 몇 주가 걸리는 기존 항우울제의 한계를 극복할 수 있습니다. 케타민의 유도체인 에스케타민은 뇌의 NMDA 수용체를 표적으로 작용하여 몇 시간 내에 기분을 개선할 수 있습니다. 이번 승인은 정신건강 치료에 있어 큰 진전입니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계 치료 저항성 우울증 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업 분석
세계의 치료 저항성 우울증 시장 : 성장률 분석
세계의 치료 저항성 우울증 시장 실적 : 규모와 성장, 2019-2024
세계의 치료 저항성 우울증 시장 예측 : 규모와 성장, 2024-2029, 2034F
세계 치료 저항성 우울증 전체 시장(TAM)
제6장 시장 세분화
세계의 치료 저항성 우울증 시장 : 약물 종류별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
선택적 세로토닌 재흡수 억제제(SSRIS)
모노아민 산화효소 억제제
삼환계 항우울제
사이케데릭스
기타 약물 클래스
세계의 치료 저항성 우울증 시장 : 투여 경로별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
경구
비경구
기타 투여 경로
세계의 치료 저항성 우울증 시장 : 유통 채널별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
병원 약국
소매 약국
온라인 약국
세계의 치료 저항성 우울증 시장 : 최종사용자별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
병원
홈케어
전문 클리닉
기타 최종사용자
세계의 치료 저항성 우울증 시장 선택적 세로토닌 재흡수 억제제(SSRIS) 종류별 하위 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
플루옥세틴
세르트랄린
파록세틴
시탈로프람
에스시탈로프람
세계의 치료 저항성 우울증 시장 모노아민 산화효소 억제제 종류별 하위 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
페넬진
트라닐시프로민
이소카복사지드
셀레길린
세계의 치료 저항성 우울증 시장 삼환계 항우울제 종류별 하위 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
아미트립틸린
노르트립틸린
이미프라민
클로미프라민
독세핀
세계의 치료 저항성 우울증 시장, 환각제 종류별 하위 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
케타민
에스케타민
실로시빈
리세르산 디에틸아미드(LSD)
3,4-메틸렌디옥시메탐페타민(MDMA)
기타 약물 클래스
세계의 치료 저항성 우울증 시장, 기타 약물 클래스 유형별 하위 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
세로토닌·노르에피네프린 재흡수 억제제(SNRI)
노르에피네프린·도파민 재흡수 억제제(NDRI)
글루탐산 모듈레이터
호르몬요법
제7장 지역별·국가별 분석
세계의 치료 저항성 우울증 시장 : 지역별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
세계의 치료 저항성 우울증 시장 : 국가별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
치료 저항성 우울증 시장 : 경쟁 구도
치료 저항성 우울증 시장 : 기업 개요
Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
Novartis AG Overview, Products and Services, Strategy and Financial Analysis
GlaxoSmithKline(GSK) plc. Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 주요 기업과 혁신적 기업
Hikma Pharmaceuticals plc
Neurocrine Biosciences Inc.
Relmada Therapeutics Inc.
Neuronetics Inc.
COMPASS Pathways
Lykos Therapeutics
Reviva Pharmaceuticals
Celon Pharma SA
BrainsWay Ltd.
Magstim Company Limited
MindMed
Alto Neuroscience
Sage Therapeutics Inc.
MindBio Therapeutics Ltd.
Reunion Neuroscience
제32장 세계의 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병
제34장 최근의 시장 동향
제35장 시장 잠재력이 높은 국가, 부문, 전략
치료 저항성 우울증 시장 2029 : 새로운 기회를 제공하는 국가
치료 저항성 우울증 시장 2029 : 새로운 기회를 제공하는 부문
치료 저항성 우울증 시장 2029 : 성장 전략
시장 동향에 기반한 전략
경쟁 전략
제36장 부록
ksm
영문 목차
영문목차
Treatment-resistant depression (TRD) is a severe and persistent form of major depressive disorder (MDD) that is characterized by an inadequate response to at least two different antidepressant treatments, each given at an adequate dose and duration. This condition leads to prolonged psychological distress and functional impairment. Individuals with TRD often require advanced therapeutic approaches, including novel pharmacological treatments, neuromodulation techniques, and personalized mental health interventions, to achieve symptom relief and improve overall well-being.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The main drug classes used in the treatment of treatment-resistant depression include selective serotonin reuptake inhibitors (SSRIs), monoamine oxidase inhibitors, tricyclic antidepressants, psychedelics, and others. SSRIs are a class of antidepressants that work by increasing serotonin levels in the brain, inhibiting its reabsorption into neurons, which enhances mood regulation and helps treat conditions such as depression and anxiety disorders. These medications are administered through various routes, including oral, parenteral, and others, and are distributed through channels such as hospital pharmacies, retail pharmacies, and online pharmacies. Key end users include hospitals, homecare settings, specialty clinics, and other healthcare providers.
The treatment-resistant depression market research report is one of a series of new reports from The Business Research Company that provides treatment-resistant depression market statistics, including treatment-resistant depression industry global market size, regional shares, competitors with a treatment-resistant depression market share, detailed treatment-resistant depression market segments, market trends and opportunities, and any further data you may need to thrive in the treatment-resistant depression industry. This treatment-resistant depression market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The treatment-resistant depression market size has grown strongly in recent years. It will grow from$1.76 billion in 2024 to $1.88 billion in 2025 at a compound annual growth rate (CAGR) of 7.1%. The growth during the historic period can be attributed to several factors, including the rising cases of treatment-resistant depression, the increasing incidence of depression, improved access to healthcare facilities, growing awareness of available treatment options, and the high prevalence of mental health disorders.
The treatment-resistant depression market size is expected to see strong growth in the next few years. It will grow to$2.46 billion in 2029 at a compound annual growth rate (CAGR) of 6.9%. The growth during the forecast period can be attributed to factors such as the rise in chronic diseases, the increasing prevalence of anxiety disorders, growing awareness of mental health issues, enhanced government initiatives, and higher healthcare expenditure. Key trends expected in the forecast period include the expansion of telemedicine and digital health, advancements in diagnostic and therapeutic technologies, efforts to reduce mental health stigma and raise awareness, the adoption of personalized medicine, and the integration of artificial intelligence in mental health treatment.
The increasing prevalence of mental disorders is expected to drive the growth of the treatment-resistant depression (TRD) market. Mental disorders encompass a wide range of conditions that affect an individual's cognitive, emotional, and behavioral functions, often resulting in significant distress and impairment in daily life. The high prevalence of these disorders is influenced by factors such as genetic predisposition, as inherited genetic variations can alter brain chemistry and increase the susceptibility to conditions such as depression, anxiety, and schizophrenia. TRD provides support for patients by offering more personalized and advanced treatment options when standard therapies fail, thereby improving their chances of recovery and overall quality of life. For example, in November 2023, the American Psychological Association (APA) reported that 50% of adults aged 18 to 34 experienced mental illnesses, the highest rate among age groups, while adults aged 35 to 44 saw the largest increase in diagnoses, with 45% reporting a mental illness. This rise in mental health conditions is contributing to the growth of the treatment-resistant depression market.
Leading companies in the treatment-resistant depression market are focused on developing innovative therapies, such as monotherapy, to address unmet patient needs, improve efficacy, and minimize side effects. Monotherapy involves the use of a single treatment or medication, as opposed to combining multiple therapies, offering a more focused approach to treating treatment-resistant depression. This strategy is particularly beneficial for patients who have not responded to several medications. For example, in January 2025, Johnson & Johnson Services Inc., a US-based pharmaceutical and medical technology company, announced the approval of SPRAVATO (esketamine) nasal spray by the U.S. Food and Drug Administration (FDA) as a fast-acting treatment for adults with treatment-resistant depression. SPRAVATO is used in conjunction with an oral antidepressant when patients have not adequately responded to at least two other antidepressants. The drug's rapid effects address the limitations of traditional antidepressants, which often take weeks to show results. As a derivative of ketamine, esketamine works by targeting the brain's NMDA receptors, potentially improving mood within hours. This approval represents a significant advancement in mental health treatment.
In October 2024, Resilience Lab, a US-based healthcare company, acquired Options MD for an undisclosed amount. This acquisition allows Resilience Lab to enhance its mental health services by integrating Options MD's specialized platform for treating severe and treatment-resistant depression. This move aims to expand access to personalized, evidence-based care. Options MD is a US-based telepsychiatry company specializing in the treatment of severe and treatment-resistant depression, bipolar disorder, post-traumatic stress disorder (PTSD), and other mental health conditions.
Major players in the treatment-resistant depression market are Pfizer Inc., Johnson & Johnson Services Inc., Abbott Laboratories, Novartis AG, GlaxoSmithKline (GSK) plc., Hikma Pharmaceuticals plc, Neurocrine Biosciences Inc., Relmada Therapeutics Inc., Neuronetics Inc., COMPASS Pathways, Lykos Therapeutics, Reviva Pharmaceuticals, Celon Pharma SA, BrainsWay Ltd., Magstim Company Limited, MindMed, Alto Neuroscience, Sage Therapeutics Inc., MindBio Therapeutics Ltd., Reunion Neuroscience.
North America was the largest region in the treatment-resistant depression market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in treatment-resistant depression report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the treatment-resistant depression market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The treatment-resistant depression market consists of revenues earned by entities by providing services such as psychiatric counseling, cognitive behavioral therapy (CBT), transcranial magnetic stimulation (TMS) therapy, electroconvulsive therapy (ECT), and ketamine infusion therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The treatment-resistant depression market includes sales of products such as esketamine nasal spray, vagus nerve stimulation (VNS) devices, deep brain stimulation (DBS) systems, neuromodulation devices, glutamate receptor modulators, and digital therapeutics. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Treatment-Resistant Depression Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on treatment-resistant depression market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for treatment-resistant depression ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The treatment-resistant depression market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Drug Class: Selective Serotonin Reuptake Inhibitors (SSRIS); Monoamine Oxidase Inhibitors; Tricyclic Antidepressant; Psychedelics; Other Drug Classes
2) By Route Of Administration: Oral; Parenteral; Other Routes Of Administration
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
4) By End-User: Hospitals; Homecare; Specialty Clinics; Other End-Users
3. Treatment-Resistant Depression Market Trends And Strategies
4. Treatment-Resistant Depression Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Treatment-Resistant Depression Growth Analysis And Strategic Analysis Framework
5.1. Global Treatment-Resistant Depression PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Treatment-Resistant Depression Market Growth Rate Analysis
5.4. Global Treatment-Resistant Depression Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Treatment-Resistant Depression Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Treatment-Resistant Depression Total Addressable Market (TAM)
6.1. Global Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Selective Serotonin Reuptake Inhibitors (SSRIS)
Monoamine Oxidase Inhibitors
Tricyclic Antidepressant
Psychedelics
Other Drug Classes
6.2. Global Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Parenteral
Other Routes Of Administration
6.3. Global Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
6.4. Global Treatment-Resistant Depression Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Homecare
Specialty Clinics
Other End-Users
6.5. Global Treatment-Resistant Depression Market, Sub-Segmentation Of Selective Serotonin Reuptake Inhibitors (SSRIS), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Fluoxetine
Sertraline
Paroxetine
Citalopram
Escitalopram
6.6. Global Treatment-Resistant Depression Market, Sub-Segmentation Of Monoamine Oxidase Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Phenelzine
Tranylcypromine
Isocarboxazid
Selegiline
6.7. Global Treatment-Resistant Depression Market, Sub-Segmentation Of Tricyclic Antidepressant, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Amitriptyline
Nortriptyline
Imipramine
Clomipramine
Doxepin
6.8. Global Treatment-Resistant Depression Market, Sub-Segmentation Of Psychedelics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Ketamine
Esketamine
Psilocybin
Lysergic Acid Diethylamide (LSD)
3,4-Methylenedioxymethamphetamine (MDMA)
Other Drug Classes
6.9. Global Treatment-Resistant Depression Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Treatment-Resistant Depression Market
9.1. China Treatment-Resistant Depression Market Overview
9.2. China Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Treatment-Resistant Depression Market
10.1. India Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Treatment-Resistant Depression Market
11.1. Japan Treatment-Resistant Depression Market Overview
11.2. Japan Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Treatment-Resistant Depression Market
12.1. Australia Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Treatment-Resistant Depression Market
13.1. Indonesia Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Treatment-Resistant Depression Market
14.1. South Korea Treatment-Resistant Depression Market Overview
14.2. South Korea Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Treatment-Resistant Depression Market
15.1. Western Europe Treatment-Resistant Depression Market Overview
15.2. Western Europe Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Treatment-Resistant Depression Market
16.1. UK Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Treatment-Resistant Depression Market
17.1. Germany Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Treatment-Resistant Depression Market
18.1. France Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Treatment-Resistant Depression Market
19.1. Italy Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Treatment-Resistant Depression Market
20.1. Spain Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Treatment-Resistant Depression Market
21.1. Eastern Europe Treatment-Resistant Depression Market Overview
21.2. Eastern Europe Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Treatment-Resistant Depression Market
22.1. Russia Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Treatment-Resistant Depression Market
23.1. North America Treatment-Resistant Depression Market Overview
23.2. North America Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Treatment-Resistant Depression Market
24.1. USA Treatment-Resistant Depression Market Overview
24.2. USA Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.2. Canada Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Treatment-Resistant Depression Market
26.1. South America Treatment-Resistant Depression Market Overview
26.2. South America Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Treatment-Resistant Depression Market
27.1. Brazil Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Treatment-Resistant Depression Market
28.1. Middle East Treatment-Resistant Depression Market Overview
28.2. Middle East Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Treatment-Resistant Depression Market
29.1. Africa Treatment-Resistant Depression Market Overview
29.2. Africa Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Treatment-Resistant Depression Market Competitive Landscape And Company Profiles